ANIK Logo

Anika Therapeutics, Inc. (ANIK) 

NASDAQ
Market Cap
$238.87M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
535 of 960
Rank in Industry
64 of 120

Largest Insider Buys in Sector

ANIK Stock Price History Chart

ANIK Stock Performance

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide …

Insider Activity of Anika Therapeutics, Inc.

Over the last 12 months, insiders at Anika Therapeutics, Inc. have bought $0 and sold $0 worth of Anika Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Anika Therapeutics, Inc. have bought $274,901 and sold $185,436 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,500 shares for transaction amount of $32,055 was made by Colleran David (EVP, General Counsel, Corp Sec) on 2022‑05‑11.

List of Insider Buy and Sell Transactions, Anika Therapeutics, Inc.

2022-05-11PurchaseEVP, General Counsel, Corp Sec
1,500
0.0104%
$21.37$32,055+22.64%
2022-03-14PurchaseEVP, General Counsel, Corp Sec
1,500
0.0109%
$26.65$39,978-3.85%
2022-03-11PurchasePresident, CEO, Director
3,813
0.0266%
$25.81$98,429-4.61%
2022-03-11Purchase
2,000
0.0133%
$24.66$49,318-4.61%
2022-03-11PurchaseEVP, CFO, Treasurer
4,000
0.0266%
$24.62$98,476-4.61%
2021-08-12PurchaseEVP, CFO, Treasurer
777
0.0053%
$40.20$31,239-23.48%
2021-08-11PurchaseEVP, CFO, Treasurer
2,850
0.0196%
$40.21$114,587-22.71%
2021-05-18Purchasedirector
2,000
0.014%
$42.86$85,720-6.92%
2021-05-12Saledirector
2,000
0.014%
$42.60$85,200-5.92%
2020-11-10Saledirector
3,446
0.0232%
$36.77$126,709+6.14%
2020-07-09SaleEVP Business Development
1,244
0.0089%
$35.15$43,727+8.80%
2020-02-26Saledirector
2,700
0.0192%
$42.68$115,236-13.87%
2019-11-08SaleChief Financial Officer
20,000
0.1389%
$59.71$1.19M-39.44%
2019-08-28Saledirector
4,355
0.031%
$57.21$249,150-27.63%
2019-08-20Saledirector
1,994
0.0141%
$55.57$110,807-24.80%
2019-08-08Saledirector
4,843
0.0345%
$56.66$274,404-24.77%
2019-07-29Saledirector
3,000
0.0222%
$55.44$166,320-17.75%
2019-02-28PurchasePresident and CEO; Director
1,000
0.0072%
$33.20$33,200+38.89%
2019-02-26Saledirector
4,000
0.0287%
$33.06$132,240+39.32%
2017-11-30SaleChief Commercial Officer
5,250
0.0356%
$54.48$286,020-23.46%

Insider Historical Profitability

2.26%
Blanchard Cheryl RPresident, CEO, Director
59992
0.4096%
$16.3110<0.0001%
QUINLAN KEVIN WChief Financial Officer
27112
0.1851%
$16.3152+3.86%
Darling Joseph GPresident and CEO; Director
22436
0.1532%
$16.3110+38.89%
Thompson Jeffery S
17121
0.1169%
$16.3114<0.0001%
Levitz Michael LEVP, CFO, Treasurer
15924
0.1087%
$16.3130<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Trigran Investments, Inc.$52.64M13.982.07M-3.12%-$1.69M5.1
BlackRock$39.65M10.531.56M+12.81%+$4.5M<0.01
Caligan Partners LP$36.47M9.681.44M+32.8%+$9.01M9.64
Dimensional Fund Advisors$20.57M5.46809,755-1.42%-$297,103.800.01
The Vanguard Group$19.65M5.22773,702+1.26%+$245,287.80<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.